Sudden neonatal death in individuals with medium-chain acyl-coenzyme A dehydrogenase deficiency: limit of newborn screening

Ulrike Mütze1 · Uta Nennstiel2 · Birgit Odenwald2 · Claudia Haase3 · Uta Ceglarek4 · Nils Janzen5,6,7 · Sven F. Garbade1 · Georg F. Hoffmann1 · Stefan Kölker1 · Dorothea Haas1

Received: 16 December 2021 / Revised: 27 January 2022 / Accepted: 13 February 2022 / Published online: 16 March 2022 © The Author(s) 2022

Abstract
Medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency is the most common disorder of mitochondrial β-oxidation of fatty acids resulting in hypoketotic hypoglycemia, hepatopathy, and often fatal outcome in undiagnosed children. Introduction of tandem mass spectrometry–based newborn screening programs in the late 1990s has significantly reduced morbidity and mortality in MCAD deficiency; however, neonatal death in individuals with early disease manifestation and severe hypoglycemia may still occur. We describe the fatal disease course in eight newborns with MCAD deficiency, aiming to raise awareness for early clinical symptoms and the life-saving treatment, and promote systematic post-mortem protocols for biochemical and genetic testing, necessary for correct diagnosis and counselling of the family if unexpected death occurred in the neonatal period.

Conclusion: Early newborn screening and awareness for clinical symptoms is lifesaving in MCAD deficiency, which may present with fatal neonatal crisis. Systematic post-mortem diagnostic protocols are needed for sudden neonatal deaths.

What is Known:
- Medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency identified by newborn screening has an excellent outcome.
- Fatal neonatal crises occur in the first days prior to screening.

What is New:
- Poor feeding, no monitoring of blood glucose, and homozygosity of the common gene variant (c.985A > G) are major risk factors for fatal neonatal crisis in MCAD deficiency.
- Post-mortem diagnostic protocols are indispensable for correct diagnosis and counselling of the family if unexpected death occurred in the neonatal period.

Keywords MCAD · Fatal disease course · Sudden neonatal death · Mortality · Neonatal screening

Abbreviations
| Abbreviation | Definition |
|--------------|------------|
| C8 | Octanoylcarnitine |
| CoA | Coenzyme A |
| DGNS | German Society for Neonatal Screening |
| MCAD | Medium-chain acyl-coenzyme A dehydrogenase |
| NBS | Newborn screening |

Introduction
Medium-chain acyl-coenzyme A (CoA) dehydrogenase (MCAD) catalyzes the initial step in the β-oxidation of medium-chain acyl-CoAs. MCAD deficiency results in a lack of energy production by reduced ketogenesis and gluconeogenesis and causes an accumulation of medium-chain CoAs and their corresponding acylcarnitines resulting in a characteristic biochemical pattern which is used for newborn screening (NBS) and selective metabolic diagnostics. MCAD is encoded by the ACADM gene and 201 pathogenic or likely pathogenic variants have been described with an additional 127 variants of uncertain significance (https://...
In natural history, individuals with MCAD deficiency (OMIN #201,450) appear completely normal until the first metabolic decompensation which typically occurs within the first few months or years of life [1, 2] in catabolic episodes induced by prolonged fasting, recurrent vomiting, and/or intercurrent infectious disease. These episodes can precipitate life-threatening hypoglycemia, lethargy, reduced consciousness, seizures, and acute hepatopathy [1, 2]. Since implementation of tandem mass spectrometry in the 1990s, MCAD deficiency is part of most NBS programs worldwide [3] and thus is identified in the early postnatal period. Preventive measures, such as avoidance of fasting and use of emergency plans to provide carbohydrates orally or intravenously during catabolism, give these patients a favorable long-term outcome [4–6]. However, neonatal metabolic decompensation due to MCAD deficiency has been reported in the first hours and days of life before NBS results are available or even prior to sampling [6–9]. These episodes led to death in up to 5% of affected patients [6, 9] and potentially severe residual morbidity in survivors [10].

Patients and methods

To identify neonatally deceased patients with MCAD deficiency in Germany since start of the expanded national NBS program in 2005 until the present year (2021), German NBS laboratories (Hannover, Leipzig, München, and Heidelberg) and the German Society for Neonatal Screening (DGNS), collecting nationwide NBS cases communicated by the German NBS laboratories, were asked in April 2021 to report all recorded cases of neonatal death of patients with MCAD deficiency since 2005.

Data collection was performed anonymized using the data set of the multicenter observational NBS study in Southwest Germany (DRKS-ID: DRKS00013329; [4]). The study was approved by the local ethics committee of the coordinating site (University Hospital Heidelberg, application no. S-104/2005). Following the study protocol, anonymized data of deceased patients are collected without informed consent of the caregivers to avoid re-traumatization of the families. The data set included NBS parameters, results of confirmatory diagnostics, and medical history (pregnancy, clinical data). The surviving sibling (patient 2b, Table 1) fulfilled all inclusion criteria [4] and parents gave informed written consent.

Statistical analyses

Boschloo’s exact test was used to analyze two-way contingency tables, and Bonferroni alpha error adjustment was applied to correct p-values in multiple comparisons.

Results

Since 2005, nine individuals with MCAD deficiency, one of them screened in another European country, have been reported by German NBS laboratories and DGNS. Median (range) age of death was 3.5 (3–6) days. Evaluation of the circumstances of death and comorbidities indicated that MCAD deficiency was causal in all but one patient (39 weeks of gestation, birth weight: 3430 g) who died at day 4 due to a total anomalous pulmonary venous connection. This patient was excluded from further analyses.

Clinical data and medical history

Clinical data and medical history are summarized in Table 1. Infants were born at term with a median (range) of 40 (39–41) weeks of gestation, median (range) birth weight of 3435 (2520–3820) g, and unremarkable postnatal adaptation (Table 1). For five patients, information on feeding were reported (n = 3 missing): In four patients (80%), poor feeding preceded fatal decompensation. Two of them had been already discharged, while in the other two metabolic decompensation was recognized and/or sudden unexpected death occurred in the maternity hospitals. Severe hypoglycemia was found in all infants in whom blood glucose had been measured during crisis (Table 1).

NBS process, results, and confirmatory diagnostics

In all but one patient (n = 7), NBS samples were taken prior to death at a median (range) age of 46 (38–72) hours, all adhering to the German regulatory specification (36–72 h; [11]; Table 2), and NBS results were available at median (range) of 5 (4–7) days. In patient #2a, no NBS sample was taken before death at the age of day 3. In the younger sibling, born 3 years later (#2b), MCAD deficiency was identified by NBS and subsequently confirmed. Retrospectively, MCAD deficiency was highly suggestive to have caused the older sibling’s (2a) sudden neonatal death, which had not been followed by any other diagnostics at that time.

All deceased newborns had massively elevated concentration of octanoylcarnitine (C8) in NBS (n = 7; median 24.3 µmol/l; reference < 0.15 µmol/l). Additionally, other
medium-chain acylcarnitines and their ratios (Table 2) were also clearly elevated. Confirmatory genetic analysis revealed homozygosity for the classic pathogenic ACADM variant c.985A>G (Lys329Glu; Table 2) for all tested patients.

**MCAD deficiency, birth prevalence, and neonatal mortality rate**

According to published data from the German NBS program (annual reports of the DGNS [12]) 9,941,846 newborns were screened in Germany from 2005 to 2018. In 968 of them, MCAD deficiency was confirmed after positive NBS [12]. This revealed a birth prevalence of about 1 in 10,300 newborns, in line with previous reports [4], and an overall neonatal MCAD mortality rate of 0.6% (Table 3). This is lower than that reported in an Australian unscreened population (7.5% [6]; p = 0.0065; Boschloo’s test; Table 3), but comparable to their screened cohort (2.4%; [6]; p = 0.42). Considering the percentage (47% [13], i.e. 455 of 968) of homozygosity for c.985A>G in screened individuals with MCAD deficiency in Germany, neonatal mortality rate for this genetic constellation was 1.3%, still in trend lower than in the unscreened Australian cohort ([6]; p = 0.051; Boschloo’s test; Table 3).

**Discussion**

In individuals with MCAD deficiency, detection by NBS and subsequent specific measures such as avoidance of fasting and reliable supply of carbohydrates during catabolic situations prevent metabolic decompensations [4] and ensure excellent long-term outcome [4–6]. However, fatal episodes of severe hyperglycemia triggered by postnatal catabolism can still occur in the first hours and days of life [6, 9].

We evaluated all reported cases of neonatal death in individuals with MCAD deficiency since introduction of MCAD deficiency in the German regular NBS panel in 2005. In all patients, lethal metabolic decompensation occurred before NBS results could be reported or even before NBS sample was taken. However, mortality rate for screened individuals with MCAD deficiency was still lower than in the pre-screening era [6, 9], demonstrating the effect of advances in neonatology and especially in screening and prevention of neonatal hypoglycemia in recent years combined with the effect of NBS in prevention of neonatal metabolic crises after abnormal results have been obtained [4].

All deceased MCAD-deficient infants were term-born and all but one were eutrophic. They were born in maternity hospitals and routine neonatal assessment was normal in all but one patient, who was excluded from our analysis.
Table 2 Results of NBS and genetic confirmation

| Child | Age at NBS sampling (h) | Sample arrival NBS lab (days after birth) | NBS report (days after birth) | C8 (µmol/l) | C10 (µmol/l) | C10:1 | C6 (µmol/l) | C0 (µmol/l) | C8/C2 | C8/C10 | C8/C12 | Genetic testing |
|-------|------------------------|------------------------------------------|-------------------------------|-------------|-------------|--------|-------------|-------------|-------|--------|--------|-----------------|
| 1     | 72                     | 5                                        | 9                             | 41.9        | n/a         | n/a    | n/a         | n/a         | n/a   | n/a    | n/a    | Homozygous c.985A > G |
| 2a    | Death before NBS samples was taken |
| 2b    | 40                     | 3                                        | 3                             | 26.4        | 2.17        | 0.9    | 4.56        | Missing     | 0.78  | 12.1   | 94     | Homozygous c.985A > G |
| 3     | 41                     | 4                                        | 4                             | 24.3        | 1.76        | 0.48   | 2.59        | 13          | 1.52  | 13.8   | 90     | Homozygous c.985A > G |
| 4     | 72                     | 6                                        | 7                             | 19.8        | 3.33        | 1.46   | 3.57        | 24          | Missing | 47.8   | 8.3    | Homozygous c.985A > G |
| 5     | 41                     | 3                                        | 4                             | 8.1         | 0.98        | 0.25   | 1.12        | 42          | Missing | 8.3    | Homozygous c.985A > G |
| 6     | 38                     | 5                                        | 5                             | 37.6        | 3.30        | 1.6    | 4.20        | 27          | Missing | 11.4   | 31     | Homozygous c.985A > G |
| 7     | 71                     | 4                                        | 5                             | 17          | 1.18        | 0.2    | 1.26        | 14          | 0.82   | 14.5   | 58     | Homozygous c.985A > G |
| 8     | 46                     | 5                                        | 5                             | 28.2        | 2.27        | 0.43   | 2.16        | Missing     | 0.85   | 12.4   | 74     | Missing         |
| All*  | N=7                    | Median (range)                            | N=7                           | 46 (38–72)  | 5 (3–6)     | 5 (4–9) | N=7                     | N=6                     | N=6   | N=4    | N=6    | Homozygous c.985A > G |

*Without individual #2b
**Normal values, Heidelberg NBS laboratory
because of severe congenital heart disease. The remaining
newborns had no evidence of concomitant diseases so that
MCAD deficiency was most likely the exclusive and pre-
ventable cause of death. However, none of these patients had
received a post-mortem autopsy. Additional underlying con-
ditions, which may have contributed to the lethal outcome,
can therefore not completely be excluded.

Apart from MCAD deficiency, none of the deceased new-
borns was at risk for hypoglycemia requiring monitoring
of blood glucose and early feeding, which might have pre-
vented early metabolic decompensation and death. Neverthe-
less, poor feeding, enhancing postnatal catabolism, which
may cause metabolic decompensation, was reported in 80%
of the patients with reliable nutritional information. As a fur-
ther complicating factor, 50% of the neonates were already
discharged from maternity hospital when fatal metabolic
crisis or sudden death occurred.

NBS showed a pattern characteristic for MCAD defi-
ciency in all patients, comparable to previous reports [13].
Genetic testing revealed for all homozygosity for the com-
mon severe ACADM gene variant (c.985 A>G) found in
about 80% of symptomatically diagnosed patients in the pre-
screening era [14] and in about 32% to 59% of neonatally
screened individuals with MCAD deficiency [5, 13]. Thus,
homozygosity for c.985 A>G is a major risk factor for neo-
natal death in MCAD patients. Therefore, a post-mortem
metabolic and genetic testing is of importance for counsel-
ing affected families and to reduce the risk for neonatal
death in siblings. Patient 2b in our cohort is the younger
sibling of 2a, in whom NBS and further diagnosis following
the sudden unexpected death had not been performed.

To prevent early deaths in neonates with unidenti-
fied MCAD deficiency, the following aspects have to be
considered:

**Timely sampling and processing of NBS**

Time of NBS sampling differs between national NBS pro-
grams [15] and ranges from, e.g. the German recommendation
for NBS sampling (age 36 and 72 h of life; [11]) to >120 h
of life in the UK [16]. However, although median age at NBS
sampling in Germany decreased from 72 to 50 h since 2003,
NBS is usually not reported before a median age of 5 days
because transport time increased [4]. As knowledge of the
diagnosis would most likely have prevented the reported
neonatal deaths [1] and mortality rates in confirmed MCAD
patients up to 25% have been reported [1, 2], all parties
involved in NBS are challenged to process NBS as recom-
Aplied on the day of sampling. Third, national mail
transportation time should be assured to be completed within
two working days. Fourth, analysis time at NBS laboratory
should not exceed 24 h, as recommended by German national
regulatory for NBS [11]. In case of outpatient births or dis-
charge from maternity units before the regular NBS sampling
time, an additional early sample at discharge should be taken
and parents should be informed to care about a timely regular
NBS by the pediatrician or midwife.

**Prevention and/or early treatment of neonatal hypoglycemia**

MCAD deficiency is an inherited metabolic disease with
safe and effective treatment, if identified early. Prevention
and/or early treatment of neonatal hypoglycemia is of utmost
importance to avoid neonatal metabolic decompensation.
The success of hypoglycemia prevention in maternity and
neonatal units is underlined by the finding that fatal decom-
pensation occurred in newborns without additional risk for
hypoglycemia (such as prematurity, small for gestational age
(SGA), large for gestational age (LGA), or maternal dia-
abetes). Most patients described in this report were born at term
and had normal weight so that specific monitoring of blood
glucose or early feeding did not seem necessary.

However, in this cohort, the majority of deceased MCAD
patients showed poor feeding and lethargy as an early sign

| Birth cohort (n) | MCAD deficiency (n) | Reported neonatal death in individuals with MCAD deficiency (mortality rate) |
|-----------------|--------------------|--------------------------------------------------------------------------|
| Australia 1994–2004 Unscreened [6] | 1,685,000 | 40 | 3 (7.5%) |
| Australia 1994–2004 Screened [6] | 810,000 | 41 | 1 (2.4%) |
| Germany 2005–2018 Screened [12] | 9,941,846 | ~455 (C.985A>G homozygous*) | 6 (1.3%) |

*Estimated number of c.985A>G homozygous patients according to [13]
of decompensation. Patient 2a had feeding difficulties and was sleepy on day 2, but no additional feeding was given at the maternity hospital. Patient 3 was lethargic on day 2, had difficulties with breastfeeding, and lost about 10% of weight. Her blood glucose was 2.1 mmol/l, which was considered normal for a newborn less than 48 h of age. Obstetricians, midwives, neonatologists, and all pediatricians should be aware that every neonate with poor feeding needs special monitoring. Apart from the most frequent neonatal differential diagnoses such as perinatally acquired infections and congenital heart defects, metabolic causes should be considered. Thus, blood glucose and blood gases should be measured in every newborn with feeding difficulties or lethargy. Early feeding and follow-up of blood glucose concentrations, if reduced, can be lifesaving for MCAD deficient patients before diagnosis. Nevertheless, screening for hypoglycemia in asymptomatic newborns is discussed controversial as it results in lower rates of exclusive breastfeeding [17].

**Post-mortem investigations**

MCAD deficiency, as several other inherited metabolic diseases, may present as sudden neonatal or infant death [18]. Finding the correct diagnosis in case of neonatal fatal metabolic decompensation or sudden unexpected death is of utmost importance because otherwise genetic counseling of the parents, including a reliable risk assessment for additional children, is not possible. If a metabolic disorder is suspected or not excluded, but no specific results have been obtained at the time of death, we recommend to collect the samples summarized in Table 4 [19]. This will also allow to identify more cases, as patient #2a, that may have been missed and remained unsolved without adequate post-mortem investigation.

**Conclusion**

In conclusion, MCAD deficiency, a treatable inherited metabolic disease, has been part of NBS programs worldwide for more than 20 years. Preventive measures allow an excellent outcome for screened individuals with MCAD deficiency. Early fatal neonatal metabolic decompensations occurring in the first days of life cannot be prevented by NBS. To further reduce mortality, we recommend sampling of NBS very early in the time frame recommended by national specifications, and additional NBS sampling for outpatient birth or early discharged children. Also, algorithms to prevent, diagnose, and treat hypoglycemia in neonates in maternity and neonatal units should be optimized. If unexpected neonatal death occurs despite these measures, there should be a specific post-mortem diagnostic protocol, which at least includes a dried blood spot card for NBS.

**Acknowledgements** We are indebted to all patients and their parents who participated in this study by sharing their data.

**Authors’ Contributions** U. Mütze and D. Haas conceptualized and designed the study. U. Mütze and D. Haas evaluated and interpreted data, drafted the initial manuscript, and reviewed and revised the final manuscript. S. F. Garbade carried out the statistical analyses and critically reviewed and revised the manuscript for important intellectual content. S. Kölker critically reviewed and revised the manuscript for important intellectual content. G.F. Hoffmann and U. Mütze critically reviewed and revised the manuscript for important intellectual content. The corresponding author had full access to all data in the study and had the final responsibility for the decision to submit for publication. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

**Funding** Open Access funding enabled and organized by Projekt DEAL. The long-term outcome study (“Long-term outcome of patients with inherited metabolic diseases after diagnosis by expanded newborn screening”) is generously supported by the Dietmar Hopp Foundation, St. Leon-Rot, Germany (grant numbers 2311221, 1DH2011117 to SK
and GFH). UM was supported by an Olympia Morata research fellowship of the Medical Faculty Heidelberg (grant number F:206852). The authors confirm independence from the sponsor; the content of the article has not been influenced by the sponsor.

Availability of data and material Not applicable.

Code availability Not applicable.

Declarations

Ethics approval This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the coordinating site (University Hospital Heidelberg, application no. S-104/2005).

Consent to participate Following the study protocol and ethical approval, anonymized data of deceased patients were collected without informed consent of the caregivers to avoid re-traumatization of the families. Written informed consent was obtained from the parents of the surviving sibling.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests. The authors confirm independence from the sponsor mentioned in the “Funding” section; the content of the article has not been influenced by the sponsor.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

References

1. Iafolla AK, Thompson RJ Jr, Roe CR (1994) Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 124(3):409–15. Epub 1994/03/01. https://doi.org/10.1016/s0022-3476(94)70363-9, PubMed PMID: 8120710.

2. Pollitt RJ, Leonard JV (1998) Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child 79(2):116–9. Epub 1998/11/03. https://doi.org/10.1136/adc.79.2.116, PubMed PMID: 9797590, PubMed Central PMCID: PMC6171765.

3. Therrell BL, Padilla CD, Loeber JG, Niesen S, Saadallah A, Borrajro GI et al (2015) Current status of newborn screening worldwide: 2015. Semin Perinatol 39(3):171–87. Epub 2015/05/17. https://doi.org/10.1053/j.semperi.2015.03.002, PubMed PMID: 25979780.

4. Mütze U, Garbade SF, Grammer G, Lindner M, Freisinger P, Grünewert SC et al (2020) Long-term outcomes of individuals with metabolic diseases identified through newborn screening. Pediatr 146(5). Epub 2020/10/15. https://doi.org/10.1542/peds.2020-0444, PubMed PMID: 33051224.

5. Wilcken B (2010) Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 33(5):501–6. Epub 2010/01/06. https://doi.org/10.1007/s10545-009-9001-1. PubMed PMID: 20494534.

6. Wilcken B, Haas M, Joy P, Wiley V, Chaplin M, Black C et al (2007) Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet (London, England) 369(9555):37–42. Epub 2007/01/09. https://doi.org/10.1016/s0140-6736(07)60029-4, PubMed PMID: 17208640.

7. Wilcken B, Carpenter KH, Hammond J (1993) Neonatal symptoms in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 69(3 Spec No):292–4. Epub 1993/09/01. https://doi.org/10.1136/adc.69.3_spec_no.292, PubMed PMID: 8215568, PubMed Central PMCID: PMCPMC1029495.

8. Anderson DR, Viau K, Botto LD, Pasquali M, Longo N (2019) Clinical and biochemical outcomes of patients with medium-chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 132(1):1–6. Epub 2019/12/15. https://doi.org/10.1016/j.ymgme.2019.11.006, PubMed PMID: 31836936.

9. Wilcken B (2008) More on medium-chain acyl-coenzyme a dehydrogenase deficiency in a neonate. N Engl J Med 358(6):647; author reply Epub 2008/02/08. https://doi.org/10.1056/NEJMct073220, PubMed PMID: 18256406.

10. Wilcken B, Hammond J, Silnik M (1994) Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 70(3):410–2. Epub 1994/05/01. https://doi.org/10.1136/adc.70.3.410, PubMed PMID: 8017963, PubMed Central PMCID: PMC6171765.

11. G-BA (2005) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die Früherkennung von Krankheiten bei Kindern bis zur Vollendung des 6. Lebensjahres (Kinder-Richtlinien) zur Einführung des erweiterten Neugeborenen-Prüfsprechersystems der Ärzte und Krankenkassen; 2005.

12. DGNS (2021) Nationale Screening Reports Deutschland 2004–2018 http://www.screening-dgns.de/reports.php.http://www.screening-dgns.de/reports.php. DGNS: 2021 [02.08.2021].

13. Maier EM, Liebl B, Röschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgenmüller B et al (2005) Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat 25(5):443–52. Epub 2005/04/16. https://doi.org/10.1002/humu.20163, PubMed PMID: 15832312.

14. Gregersen N, Blakemore AL, Winter V, Andresen B, Kolvraa S, Bolund L et al (1991) Specific diagnosis of medium-chain acyl-CoA dehydrogenase deficiency in dried blood spots by a polymerase chain reaction (PCR) assay detecting a point-mutation (G985) in the MCAD gene. Clin Chim Acta 203(1):23–34. Epub 1991/11/09. https://doi.org/10.1016/0002-0820(91)90153-4, PubMed PMID: 1769118.

15. Loeber JG, Burgard P, Cornel MC, Rietveld PA, Weinreich SS, Rupp K et al (2012) Newborn screening programmes in Europe: arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis 35(4):603–11. Epub 2012/05/04. https://doi.org/10.1007/s10545-012-9483-0, PubMed PMID: 22552820.

16. GOV.UK (2020) Guidance - Newborn blood spot sampling guidelines: quick reference guide https://www.gov.uk/government/publications/newborn-blood-spot-screening-sampling-guidelines/quick-reference-guide: GOV.UK 2020 [cited 2021 05.08.2021].

17. Mukhopadhya S, Wade KC, Dhasasia MB, Skerritt L, Chou JH, Dukhovny D et al (2020) Clinical impact of neonatal hypoglycemia screening in the well-baby care. J Perinatol 40(9):1331–8. Epub 2020/03/11. https://doi.org/10.1038/s41372-020-0641-1, PubMed PMID: 32152490, PubMed Central PMCID: PMCPMC7442584.
18. van Rijt WJ, Koolhaas GD, Bekhof J, Heiner Fokkema MR, de Koning TJ, Visser G et al (2016) Inborn errors of metabolism that cause sudden infant death: a systematic review with implications for population neonatal screening programmes. Neonatology 109(4):297–302. Epub 2016/02/26. https://doi.org/10.1159/000443874. PubMed PMID: 26907928.

19. Zschocke J, Hoffmann GF (2021) Vademecum metabolicum: diagnosis and treatment of inborn errors of metabolism. Foreword by William L. Thieme, Nyhan, San Diego, USA

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Ulrike Mütze1· Uta Nennstiel2· Birgit Odenwald2· Claudia Haase3· Uta Ceglarek4· Nils Janzen5,6,7· Sven F. Garbade1· Georg F. Hoffmann1· Stefan Kölker1· Dorothea Haas1

Uta Nennstiel  
uta.nennstiel@lgl.bayern.de

Birgit Odenwald  
Birgit.Odenwald@lgl.bayern.de

Claudia Haase  
claudia.haase@helios-gesundheit.de

Uta Ceglarek  
Uta.Ceglarek@medizin.uni-leipzig.de

Nils Janzen  
n.janzen@metabscreen.de

Sven F. Garbade  
Sven.Garbade@med.uni-heidelberg.de

Georg F. Hoffmann  
Georg.Hoffmann@med.uni-heidelberg.de

Stefan Kölker  
Stefan.Koelker@med.uni-heidelberg.de

Dorothea Haas  
Dorothea.Haas@med.uni-heidelberg.de

1 Division of Child Neurology and Metabolic Medicine, Department of General Pediatrics, Center for Child and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany

2 Screening Center, Bavarian Health and Food Safety Authority (LGL), Oberschleissheim, Germany

3 Klinik Für Kinder- und Jugendmedizin, Helios Klinikum Erfurt, Erfurt, Germany

4 Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, University of Leipzig, Leipzig, Germany

5 Screening-Labor Hannover, Hannover, Germany

6 Department of Clinical Chemistry, Hannover Medical School, Hannover, Germany

7 Division of Laboratory Medicine, Centre for Children and Adolescents, Kinder- und Jugendkrankenhaus Auf der Bult, Hannover, Germany